Arrowstreet Capital’s Trinity Biotech TRIB Stock Holding History

Arrowstreet Capital’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-191	Closed	-$172K	–	1238
2017 Q2	$172K	Sell	191 -46	-19%	-$39.1K	﹤0.01%	1009
2017 Q1	$212K	Buy	+237	New	+$222K	﹤0.01%	1194
2016 Q2	–	Sell	-585	Closed	-$1.02M	–	1508
2016 Q1	$1.02M	Sell	585 -210	-26%	-$334K	﹤0.01%	971
2015 Q4	$1.4M	Buy	795 +476	+149%	+$843K	0.01%	896
2015 Q3	$547K	Sell	319 -58	-15%	-$140K	﹤0.01%	1074
2015 Q2	$1.02M	Sell	377 -99	-21%	-$257K	0.01%	811
2015 Q1	$1.38M	Sell	476 -530	-53%	-$1.47M	0.01%	658
2014 Q4	$2.64M	Sell	1,006 -124	-11%	-$321K	0.02%	643
2014 Q3	$3.1M	Buy	1,130 +905	+402%	+$2.94M	0.02%	500
2014 Q2	$776K	Sell	225 -457	-67%	-$1.62M	﹤0.01%	758
2014 Q1	$2.48M	Sell	682 -241	-26%	-$948K	0.02%	607
2013 Q4	$3.48M	Buy	923 +816	+763%	+$2.94M	0.02%	531
2013 Q3	$349K	Buy	+107	New	+$313K	﹤0.01%	837

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Arrowstreet Capital's TRIB Position: Q3 2017 in Review

Arrowstreet Capital sold out of Trinity Biotech (TRIB) in Q3 2017, closing a stake of 191 shares — an estimated $172K sold.

Arrowstreet Capital first reported a position in TRIB in Q3 2013 and held it in 13 quarters. The position peaked at $3.48M in Q4 2013. 52 funds tracked by Wall St. Rank hold TRIB as of Q3 2017.

Arrowstreet Capital reported no remaining Trinity Biotech position as of Q3 2017 after selling out during the quarter.
Arrowstreet Capital sold 191 Trinity Biotech shares in Q3 2017, an estimated $172K.
Arrowstreet Capital first reported a position in Trinity Biotech in Q3 2013 and held it in 13 quarters.
Arrowstreet Capital's Trinity Biotech position peaked at $3.48M in Q4 2013.
52 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2017.

Based on Arrowstreet Capital's 13F filing for Q3 2017, filed 14 Nov 2017.